Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer

Cancer Letters

Volumn 207, Issue 1, 2004, Pages 109-115

  Ishida, Hideyuki ^a,b   Miwa, Hideaki ^a   Tatsuta, Masayuki ^a   Masutani, Seizo ^a   Imamura, Hiroshi ^a   Shimizu, Junzo ^a   Ezumi, Koji ^a   Kato, Hitoshi ^a   Kawasaki, Takatoshi ^a   Furukawa, Hiroshi ^a   Kawakami, Hitoshi ^a  

^a SAKAI MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

CEA; Dukes' C colorectal cancer; Ki 67 antigen; Prognostic marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; KI 67 ANTIGEN;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL CLASSIFICATION OF DISEASES; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA; SCORING SYSTEM; SURVIVAL TIME; TISSUE SECTION;

AGED; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12144288556     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.10.032     Document Type: Article

References (18)

1. Muto T., Kotake K., Koyama Y. Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993. Int. J. Clin. Oncol. 6:2001;171-176.
2. Kubota Y., Petras R.E., Easley K.A., Bauer T.W., Tubbs R.R., Fazio V.W. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer. 70:1992;2602-2609.
3. Wilson M.S., Anderson E., Bell J.C., Pearson J.M., Haboubi N.Y., James R.D., Schofield P.F. An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas. Surg. Oncol. 3:1994;263-273.
4. Kressner U., Lindmark G., Gerdin B., Pahlman L., Glimelius B. Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res. 15:1995;2755-2761.
5. Ofner D., Grothaus A., Riedmann B., Larcher P., Maier H., Bankfalvi A., Schmid K.W. MIB1 in colorectal carcinoma: its evaluation by three different methods reveals lack of prognostic significance. Anal. Cell. Pathol. 12:1996;61-70.
6. Jansson A., Sun X.F. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. Acta Pathol. Microbiol. Immunol. Scand. 105:1997;730-734.
7. Kyzer S., Gordon P.H. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis. Colon Rectum. 40:1997;322-325.
8. Petrowsky H., Sturm I., Graubitz O., Kooby D.A., Staib-Sebler E., Gog C., et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur. J. Surg. Oncol. 27:2001;80-87.
9. UICC. TNM Classification of Malignant Tumors. Fifth ed. 1997;Springer, Berlin.
10. Ishida H., Furukawa H., Tatsuta M., Masutani S., Imamura H., Shimizu J., et al. The relationship between the number of metastatic lymph nodes and prognosis of patients with Dukes C colon cancer. Nippon Shokakigeka Gakkai Zasshi. 35:2002;369-373. (in Japanese).
11. Moreno C.G., Cerdan M.F.J., Maestro de las C.M.L., Martinez C.S., Ortega M.D., Pardo M.M., Balibrea C.J.L. Serum and tissue CEA in colorectal cancer: clinical relevance. Rev. Esp. Enferm. Dig. 90:1998;391-401.
12. Tabuchi Y., Nakamura T., Kuniyasu T., Ohno M., Usami M., Kuroda Y. Immunohistochemical p 53 protein expression in advanced colorectal cancer lesions: no association with prognostic variables or survival. Bull. Health Sci. Kobe. 15:1999;27-34.
13. Sugo H., Takamori S., Kojima K., Beppu T., Futagawa S. The significance of p53 mutation as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg. Today. 29:1999;849-855.
14. Bazan V., Migliavacca M., Zanna I., Tubiolo C., Corsale S., Calo V., et al. DNA ploidy S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J. Cancer Res. Clin. Oncol. 128:2002;650-658.
15. Yamada N., Chung Y.S., Maeda K., Sawada T., Ikehara T., Nishino H., et al. Increased expression of sialyl Lewis A and sialyl Levis X in liver metastases of human colorectal carcinoma. Invasion Metastasis. 15:1995;95-102.
16. Tatebe S., Ishida M., Kasagi N., Tsujitani S., Kaibara N., Ito H. Apotosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal-deoxynucleotidyl-transferase- mediated dUTP-biotin nick end labeling. Int. J. Cancer. 65:1996;173-177.
17. Mann B., Gratchev A., Bohm C., Hanski M.L., Foss H.D., Demel G., et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br. J. Cancer. 79:1999;1262-1269.
18. Agui T., Mcconkey D.J., Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res. 22:2002;1769-1776.